Truist Financial Begins Coverage on Coherus BioSciences (NASDAQ:CHRS)

Truist Financial assumed coverage on shares of Coherus BioSciences (NASDAQ:CHRS – Get Rating) in a report published on Monday morning, The Fly reports. The firm issued a buy rating and a $24.00 target price on the biotechnology company’s stock. Several other research firms also recently weighed in on CHRS. HC Wainwright dropped their price target […]

Related Keywords

Coherus Biosciences ,Steve Glover ,Alan Herman ,Doug Farrar ,Dennism Lanfear ,Vanguard Group Inc ,Geode Capital Management ,Coherus Biosciences Inc ,Coherus Biosciences Company Profile ,Blackrock Inc ,Barclays ,Truist Financial ,Get Rating ,Moderate Buy ,Street Corp ,Capital Management ,Redwood City ,Coherus Biosciences Daily ,Nasdaq Chrs ,Chrs ,Medical ,Initiated Coverage ,Truist Financial Co ,